tirzepatide negatives Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management Zepbound: How It Works, How

The SURMOUNT-5 trial (Aronne et al., NEJM 2025) showed that tirzepatide, a dual GIPGLP-1 receptor agonist, outperforms semaglutide in reducing weight and cardiometabolic risk in adults with obesity without diabetes

Semaglutide dosing typically follows a 4-week titration protocol starting at 0.25 mg, escalating to therapeutic ranges of 1.72.4 mg weekly

Ozempic, generically known as Liraglutide or Semaglutide, has become a popular medication for weight loss

Are the best GLP-1 products yet to come

Explore how GLP1 therapies can improve MASLD even in nonobese, nondiabetic patients and refine liverfirst treatment strategies.

Compounded semaglutide/tirzepatide will phase out by late May 2025, so prepare to switch to FDA-approved products